Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis
المؤلفون المشاركون
Wang, Haili
Fedorak, Richard N.
Ma, Christopher
Beilman, Candace L.
Wong, Karen
Halloran, Brendan P.
Thanh, Nguyen Xuan
Ung, Victoria
Kroeker, Karen I.
Lee, Thomas
Jacobs, Phil
Ohinmaa, Arto
المصدر
Canadian Journal of Gastroenterology and Hepatology
العدد
المجلد 2016، العدد 2016 (31 ديسمبر/كانون الأول 2016)، ص ص. 1-11، 11ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2016-10-03
دولة النشر
مصر
عدد الصفحات
11
التخصصات الرئيسية
الملخص EN
Background.
Adalimumab is effective for the maintenance of remission in patients with moderate-to-severe ulcerative colitis (UC).
Currently, biologic therapies are used in cases where patients fail conventional medical therapies.
If biologic therapies are not available, patients often choose to remain in an unwell state rather than undergo colectomy.
Objective.
The aim of the study was to evaluate the cost-effectiveness of adalimumab in patients with UC where adalimumab was readily available compared to not available.
Methods.
A previously validated Markov model was used to simulate disease progression of patients with UC who are corticosteroid-dependent and/or did not respond to thiopurine therapy.
Utility scores and transition probabilities between health states were determined by using data from randomized controlled trials and real-life observational studies.
Costs were obtained from the Ontario Case Costing Initiative and the Alberta Health Schedule of Medical Benefits.
Results.
The incremental cost-effectiveness ratios for readily available adalimumab treatment of UC were $40,000 and $59,000 per quality-adjusted life year, compared with ongoing medical therapy in an unwell state, at 5-year and 10-year treatment time horizons, respectively.
Conclusion.
Considering real-life patient preferences to avoid colectomy, adalimumab is cost-effective according to a willingness-to-pay threshold of $80,000 for treatment of UC.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Beilman, Candace L.& Thanh, Nguyen Xuan& Ung, Victoria& Ma, Christopher& Wong, Karen& Kroeker, Karen I.…[et al.]. 2016. Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis. Canadian Journal of Gastroenterology and Hepatology،Vol. 2016, no. 2016, pp.1-11.
https://search.emarefa.net/detail/BIM-1099887
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Beilman, Candace L.…[et al.]. Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis. Canadian Journal of Gastroenterology and Hepatology No. 2016 (2016), pp.1-11.
https://search.emarefa.net/detail/BIM-1099887
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Beilman, Candace L.& Thanh, Nguyen Xuan& Ung, Victoria& Ma, Christopher& Wong, Karen& Kroeker, Karen I.…[et al.]. Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis. Canadian Journal of Gastroenterology and Hepatology. 2016. Vol. 2016, no. 2016, pp.1-11.
https://search.emarefa.net/detail/BIM-1099887
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1099887
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر